Bioavailability Challenge

BE/BA, FDA, bioRASI, GDUFA

BE/BA sites must be logged with US FDA under GDUFA

By Gareth Macdonald

CROs conducting bioequivalence and bioavailability (BE/BA) studies for generics firms will have to log details of their sites with the US FDA under new ‘self-identification’ rules.